TY - JOUR
T1 - Priorities in Cardio-Oncology Basic and Translational Science
T2 - GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review
AU - Salloum, Fadi N.
AU - Tocchetti, Carlo G.
AU - Ameri, Pietro
AU - Ardehali, Hossein
AU - Asnani, Aarti
AU - de Boer, Rudolf A.
AU - Burridge, Paul
AU - Cabrera, José Ángel
AU - de Castro, Javier
AU - Córdoba, Raúl
AU - Costa, Ambra
AU - Dent, Susan
AU - Engelbertsen, Daniel
AU - Fernández-Velasco, María
AU - Fradley, Mike
AU - Fuster, José J.
AU - Galán-Arriola, Carlos
AU - García-Lunar, Inés
AU - Ghigo, Alessandra
AU - González-Neira, Anna
AU - Hirsch, Emilio
AU - Ibáñez, Borja
AU - Kitsis, Rickard N.
AU - Konety, Suma
AU - Lyon, Alexander R.
AU - Martin, Pilar
AU - Mauro, Adolfo G.
AU - Mazo Vega, Manuel M.
AU - Meijers, Wouter C.
AU - Neilan, Tomas G.
AU - Rassaf, Tienush
AU - Ricke-Hoch, Melanie
AU - Sepulveda, Pilar
AU - Thavendiranathan, Paaladinesh
AU - van der Meer, Peter
AU - Fuster, Valentin
AU - Ky, Bonnie
AU - López-Fernández, Teresa
AU - International Cardio-Oncology Society
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023
Y1 - 2023
N2 - Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.
AB - Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.
KW - anthracyclines
KW - basic research
KW - cancer
KW - cardiac arrhythmias
KW - cardio-oncology
KW - cardiotoxicity
KW - chemotherapy
KW - immunotherapy
KW - translational research
U2 - 10.1016/j.jaccao.2023.08.003
DO - 10.1016/j.jaccao.2023.08.003
M3 - Review article
C2 - 38205010
AN - SCOPUS:85174025308
SN - 2666-0873
VL - 5
SP - 715
EP - 731
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 6
ER -
